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Cyclosporine 
Cyclosporine is commonly used as an immunosuppressive agent in organ 
transplanted and bone marrow transplanted patients worldwide (Wiesner, 
1998;Walter et al., 2000;Somech and Doyle, 2007;Adhikary et al., 2008). 
 
History of cyclosporine 
 
Its discovery took place in the Sandoz Laboratory in Basel, Switzerland in January 
1972. 
For many years there had been a profound need to reduce or eliminate the cytotoxic 
effects of immunosuppressive agents at that time. The main goal for development of a 
new agent was to successfully transplant a solid organ taken from a deceased 
individual into a patient with a failing organ system. Methotrexate, 
cyclophosphamide, and 6-mercaptopurine (6-MP) had been tried as 
immunosuppressive agents, but showed high rejection rates, significant toxicities, and 
poor graft survival in both animal models and human trials. The novel 
immunosuppressant Cyclosporine A (CyA), with its ability to suppress the immune 
system without affecting other cells significantly, made a revolution in organ 
transplantation in the 70’s. 
 
The principal discoverers were a team of scientists within different fields of 
medicine, lead by two Swiss researchers named Jean F. Borel and Hartmann F. 
Stähelin. It involved a screening program with the antitumor agent ovacilin. Samples 
from the soil of different locations around the world were collected, and the 
microorganisms from the soil were tested for anti-fungal and anti-bacterial activity. 
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The successful result from this screening program was largely contributed by the 
revelation of metabolites from a new strain of fungi imperfecti, found in soil from 
Wisconsin in the United States and Hardangervidda in Norway (Stiller, 
1999;Langone and Helderman, 2004;Rezzani, 2004). Extracted metabolites from the 
fungal mycelia were called cyclosporine, because they were cyclic compounds found 
in spores. Later, nearly 30 variations of naturally extracted cyclosporines have been 
revealed (Langone and Helderman, 2004). All of these have a chemical structure of 
11 amino acids and mostly differ from one another by only one single amino acid 
locus. 
 
Sandoz laboratory put effort into making a potent immunosuppressive agent by 
researching both the natural derivatives and some newly developed synthetic 
derivatives of Cyclosporine A. Although the researchers pursued to both find a more 
potent and less nephrotoxic variant of cyclosporine. Among the compounds tested, 
the earliest version, namely Cyclosporin A, which proved to be the most potent. The 
less nephrotoxic Cyclosporin G was thought to be a decent alternative, but was found 
inferior in suppressing the immune system (Langone and Helderman, 2004). In 1976, 
Jean F. Borel concluded that their new discovery was efficient in both suppressing 
the antibody- and cell-mediated immune response (Borel et al., 1994;Langone and 
Helderman, 2004). Lack of bone marrow suppression was part of the conclusion as 
well. The elimination of anemia, leukopenia and thrombocytopenia as adverse effects 
made cyclosporine an interesting subject for further testing. 
 
Dr Roy Calne et al. in Cambridge made a case series in 1978 describing cyclosporine 
as a potent immunosuppressant, which led to a large demand for cyclosporine to be 
produced (Calne et al., 1979;Langone and Helderman, 2004). However, after the 
research group had performed enough transplants, they published an article 
describing several potential deleterious adverse effects of cyclosporine. The results 
 5 
from the trials revealed high rates of lymphomas and mortality (Calne et al., 1979). 
The nephrotoxic adverse effect of cyclosporine was explained by Calne et al. as graft 
dysfunction and was believed to be caused by acute rejection of transplanted kidneys. 
Thus the nephrotoxic effects of cyclosporine were not recognized until later.  
 
After the new immunosuppressive agent was recognized and made known, a need to 
study its biochemical actions presented itself. Another goal was to develop ways to 
increase the efficiency of intestinal absorption. Although the cyclosporine was 
extracted for the first time in 1972, it wasn’t commercially available until 1983 when 
Sandimmune® was released. It was first only available as a liquid concoction 
depending on the patient’s bile to be absorbed. This, as well as splitting into 12-hour 
doses, would eliminate some of the difficulties related to oral absorption. One of the 
main targets was to keep the serum levels as constant as possible in order to avoid 
neurological adverse effects as serum concentration of Cyclosporine A [CyA] 
peaked.  
 
The availability of cyclosporine as a virtually unchallenged immunosuppressant in 
transplantation medicine had been going on for many years since its discovery. In 
fact, it wasn’t until 1997 when a macrocyclic lactone derived from actinomyces was 
found, that cyclosporine would finally meet serious competition. This new 
calcineurin inhibitor was named tacrolimus, commercially known as 
Prograf®(Langone and Helderman, 2004). Several studies comparing the 
immunosuppressive effects and adverse effect profiles of tacrolimus and 
cyclosporine, conclude that tacrolimus significantly reduces the risks of death after 
liver transplantation, graft loss, acute rejection and steroid-resistant rejection (Haddad 
et al., 2006;McAlister et al., 2006). According to many clinical studies, tacrolimus 
also increases the risk of new-onset diabetes. Differences between tacrolimus and 
cyclosporine will be discussed in detail later. 
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Therapeutic effects 
 
The biochemical effect of calcineurin inhibitors, such as cyclosporine and tacrolimus, 
is ultimately the inhibition of T-cell activation (Smith et al., 2003;Taylor et al., 2005). 
The underlying mechanism for this is the blocking of Ca2+ activation of calcineurin 
when the T-cell is stimulated by antigen. Binding of foreign antigen to receptors on 
the T-cell surface leads to several signalling pathways, which in turn increase 
intracellular calcium concentration [Ca2+]. Increased [Ca2+] activates calmodulin and 
calcineurin B, which then activate the catalytic subunit of calcineurin called 
calcineurin A. This phosphatase dephosphorylates the nuclear factor of activated T-
cell (NF-AT) and permits the NF-AT to enter the nucleus. By altering the expression 
of genes specific for T-cells, it influences synthesis and release of interleukin-2 (IL-
2), which is a regulator of T-cell proliferation and differentiation. IL-2 has both 
autocrine and paracrine actions on T-cells. The inhibition of the calcineurin complex 
also counteracts the release of T-cell–derived lymphokines, including IL-2, IL-3, IL-4 
and gamma interferon This in turn inhibits the clonal expansion of helper and 
cytotoxic T-cells. In order to bind to calcineurin, cyclosporine is first bound to 
cyclophilin in the cytosol. The principal antagonistic action of cyclosporine is 
binding to the catalytic subunit of the calcineurin complex, leading to decreased 
dephosphorylation of NF-AT, and over the last steps decreasing T-cell proliferation 
and growth. Tacrolimus (FK-506) on the other hand, interacts with FK-506 binding 
protein (FKBP) before binding to the calcineurin subunit. 
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Interactions and adverse effects 
 
Even though cyclosporine and tacrolimus ultimately have the same mechanism of 
action, several studies have concluded that they only to a certain degree share the 
same profile of adverse effects (Paul, 2001;Smith et al., 2003). Smith et al. have 
described that both agents are acutely and cronically nephrotoxic and causes 
hyperkalemia and hypomagnesemia to a similar degree. The same group also 
concludes that cyclosporine tends to cause hyperlipidemia, hypertension, gingival 
hyperplasia and hypertrichosis more frequently compared to tacrolimus. The latter on 
the other hand, tends to have more neurological and gastrointestinal adverse effects 
than cyclosporine, in addition to an increased risk of hyperglycemia. Careful 
monitoring of serum concentrations is important because of a narrow therapeutic 
window for both agents, as well as known interactions with several other drugs. 
Interference with cytochrome P450 3A4 (CYP3A4), a member of the cytochrome 
P450 mixed-function oxidase system, is the main problem. Drugs such as rifampine, 
Phenobarbital, phenytoine, nafcilline and carbamazepine all decrease serum [CyA] 
and [FK506] by inducing CYP-3A4, while macrolides, antifungal agents and some 
calcium inhibitors such as verapamil increase serum concentrations by inhibiting 
CYP3A4. It is also important to warn patients against intake of grapefruit or 
grapefruit juice along with cyclosporine, as it is known to inhibit CYP3A4.  
 
The therapeutic effects of cyclosporine are relatively well-known. However, it has 
been found a clear connection between cyclosporine use and vasoconstriction in 
multiple organs. One of the most common adverse effects of cyclosporine use is its 
effects leading to nephrotoxicity. Clinical and experimental trials have shown that a 
supratherapeutic dose of CyA may lead to reduced kidney function. It is believed that 
cyclosporine-induced constriction of the afferent arteries to the kidneys is causing an 
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altered renal circulation. This is also confirmed by studies showing reduced renal 
blood flow and glomerular filtration rate with calcineurin inhibitor treatment. The 
mechanisms of this might be an imbalance between concentrations of the constricting 
thromboxane A2 and the dilating prostaglandin E2 (Butterly et al., 2000;Olyaei et al., 
2001). It has also been shown that CyA may activate the sympathetic nervous system, 
leading to increased systemic vasoconstriction. Some studies have concluded that 
CyA enhances the release of endothelin-1, constricting the vessels even further 
(Butterly et al., 2000;Prevot et al., 2000;Wilasrusmee et al., 2003). The role of nitric 
oxide (NO) is another hypothesis. NO is known to be an important regulator of renal 
vascular tone, and CyA is thought to be interfering with the production of NO.  
 
Although the nephropathy is reversible in short-term CyA treatment, a prolonged 
cyclosporine-induced vasoconstriction may lead to acute tubular sclerosis and 
irreversible lesions in the tubular interstitium (Olyaei et al., 2001). Finally, this may 
cause chronic and irreversible nephrotoxicity. 
 
The connection between diabetes mellitus and the use of calcineurin inhibitors is well 
documented (Smith et al., 2003;Rezzani, 2004;Guerra et al., 2007;Vincenti et al., 
2007). In the case of CyA, insulin production and secretion is inhibited, while the 
volume of ß-cells in the Islets of Langerhans is decreased(Rezzani, 2004). Some 
trials show that organ transplanted patients with tacrolimus treatment have a higher 
risk of hyperglycaemia and diabetes mellitus than respective patients undergoing 
CyA treatment (Smith et al., 2003;Rezzani, 2004;Guerra et al., 2007;Vincenti et al., 
2007). 
 
Hypertension is a common adverse effect caused by cyclosporine A use. Systemic 
vasoconstriction leading to hypertension within only a few days of cyclosporine 
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administration has been documented. A typical characteristic of this hypertension is 
the lack or reversal of nocturnal fall in systemic blood pressure. This has lead to 
symptoms like nocturnal headache and increased nocturnal urination. An altered 
circadian rhythm is thought to be the culprit of these symptoms. In some studies, 
some of the patients developed retinal hemorrhages and central nervous symptoms in 
addition to left ventricular hypertrophy, lacunar strokes and microalbuminuria 
(Ventura et al., 1997;Rezzani, 2004). 
 
CyA treatment is associated with an increased risk of hyperlipidemia, i.e. increased 
levels of LDL-cholesterol and triglyserides. Studies have concluded that the risk is 
higher in CyA treatment compared with tacrolimus, and some trials have shown a 
decrease in blood lipids after conversion from CyA to tacrolimus. In the same trials, 
the systemic blood pressure was higher during administration of CyA compared with 
that of tacrolimus (Calne et al., 1998;Paul, 2001;Guerra et al., 2007;Vincenti et al., 
2007). 
 
Seizure is one known  neurological adverse effect of CyA use. It may be influenced 
by associated factors such as fluid retention, hypertension, high-dose steroids, graft 
dysfunction and demyelination. Hypomagnesaemia, which can be caused by CyA 
itself, might be a contributor as well, but some trials show that some patients had 
seizures although their magnesium levels were within normal range. Multiple other 
neurological complications of CyA use include neuralgia, paresthesia, confusion, 
hemiplegia, tremor, occipital seizures, ataxia and transient cortical blindness 
(Rezzani, 2004). 
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Clinical use and efficacy of calcineurin inhibitors 
-    Liver transplantation 
 
Several studies have described the efficacy of cyclosporine and tacrolimus in liver 
graft survival (Pichlmayr et al., 1997;Wiesner, 1998;O'Grady et al., 2002). A 
randomised study involving 529 patients compared graft survival with the 
administration of tacrolimus combined with steroids and CyA combined with 
aziathropine and steroids (Pichlmayr et al., 1997). The incidence of acute, recurrent 
acute, and chronic rejection after 3 years post-transplant, were substantially lower 
among the patients receiving tacrolimus, but the graft and patient survival were at the 
same level. Another trial with the same amount of patients undergoing post-
transplant treatment, concluded that the incidence of acute rejection was significantly 
lower in the tacrolimus treated group 5 years post-transplant, although the incidence 
beyond the first year of immunosuppressive therapy was similar (Wiesner, 1998). 
Graft and patient survival after 5 years was equal. 
 
- Renal transplantation 
 
Several trials comparing the effects of CyA and tacrolimus in immunosuppressive 
treatment of kidney transplantation have been made with follow-ups after 6 and 24 
months. The results were quite similar for both immunosuppressants in graft and 
patient survival, but with clearly less acute rejection among the patients undergoing 
treatment with tacrolimus (Pirsch et al., 1997;Ahsan et al., 2001;Margreiter, 2002). 
Although there are studies concluding the beneficial use of tacrolimus in terms of 
acute graft rejection, there are no evidence that tacrolimus improves graft survival 
over a longer period of time. A study executed in Europe examined 451 patients 
receiving either tacrolimus or CyA combined with steroids and aziathropine (Mayer 
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et al., 1997). Patient and graft survival rates were similar at 5 years post-transplant, 
but the chronic rejection rate was substantially lower in tacrolimus treated patients 
(Mayer, 2002). In this case, the difference was 6.6% for tacrolimus versus 15.3% for 
cyclosporine. There are evidence that immunosuppressive treatment with tacrolimus 
is beneficial in some selected subgroups such as patients with delayed function. One 
trial concluded that graft survival rates are significantly increased in tacrolimus 
therapy compared with CyA treatment (Gonwa et al., 2003). 
 
 
-     Stem cell transplantation  
 
Two large randomized trials have compared the combination of CyA and 
methotrexate with tacrolimus and methotrexate in stem cell allograft transplantation 
(Ratanatharathorn et al., 1998;Nash et al., 2000). Both concluded that the incidence 
of acute graft-versus-host-disease (GVHD) was clearly lower in patients undergoing 
tacrolimus treatment, although the difference in chronic GVHD rates after 2 years 
was marginal. One trial even concluded that tacrolimus administration in stem cell 
transplantation from siblings had a lower rate of patient survival than treatment with 
CyA (Ratanatharathorn et al., 1998). The administration of mycophenolate mofetil in 
combination with CyA has been compared with the standard CyA/metothrexate 
treatment (Bolwell et al., 2004). The results were similar rates of GVHD for both 
combinations and comparable rates of overall survival. However, 
CyA/mycophenolate showed a faster engraftment than CyA/methotrexate in the same 
trial. 
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-     Cardiac transplantation 
 
Trials have been made in Europe and the United States comparing the efficacy of an 
oil-based CyA formulation with the combination of tacrolimus, aziathropine and 
steroids (Taylor et al., 1999;Reichart et al., 2001). Heart graft survival and patient 
survival rates were comparable one year after transplantation, while tacrolimus 
proved to induce less hyperlipidemia and hypertension than CyA. Another large 
study examining a time span of 18 months showed similar results in patient and graft 
survival but also concluded that recurrent graft survival was slightly lower in 
tacrolimus-treated patients (Grimm et al., 2006). One unique source of error after 
heart transplantation was the possible development of coronary allograft 
vasculopathy (CAV). So far there is no evidence that CyA or tacrolimus reduce the 
risk of this complication during long-term follow-up (Keogh, 2004). Indirectly 
however, the beneficial properties of tacrolimus involving hyperlipidemia, glucose 
metabolism and hypertension might be preferable in patients who develop CAV after 
cardiac transplantation. The incidence of CAV was increased in patients receiving 
steroids in combination with both CyA and tacrolimus. As for immunosuppression in 
liver and renal transplantation, the conclusion for cardiac transplantation was that 
CyA and tacrolimus have about the same efficacy on patient and graft survival, and 
the choice of which agent to use depends on the adverse effect profile that suits best 
for each patient individually. 
 
Case report: Patient undergoing cyclosporine A treatment developed bilateral 
optic disc swelling. 
A heart transplanted patient undergoing CyA treatment for 15 years experienced 
impairment of the visual field and reduced visual acuity due to bilateral optic disc 
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swelling. During the preceding 15 years, the patient’s vision was normal. After 
diagnosing optic disc swelling, the patient’s CyA administration was substituted by 
everolimus. His symptoms improved over a time span of 4 months with no further 
significant improvement after 7 months. 
 
Previous case reports have shown possible ocular adverse effects of CyA, but this 
case was unusual because of the long time span between start of CyA administration 
and the onset of signs and symptoms. By comparison, other trials have shown onset 
of symptoms as early as after 30 and even 12 months of CyA use. To our knowledge, 
no previous trials concerning heart transplanted patients with cyclosporine-induced 
optic disc edema are known.  
 
Different studies have shown variation of remission of visual signs and symptoms 
from 5 days to 8 months after CyA withdrawal (Avery et al., 1991;Cruz et al., 1996). 
These studies describe the visual adverse effects of CyA as completely reversible. In 
our case, improvement started 4 months upon cessation of Cya with full remission of 
the optic disk edema within 7 months. The patient experienced however sequelae of 
optic disc swelling in form of persistent mild visual field defects and slightly 
impaired visual acuity.  
 
Causes of optic disc swelling include mass lesions, sinus venous thrombosis, 
hypertensive papillopathy, diabetic papillopathy, anterior ischemic optic neuropathy 
(both nonartetitic and arteritic), optic neuritis, uremia and disorders of the 
parathyroidea. They were all excluded in our patient. Idiopathic intracranial 
hypertension (pseudotumor cerebri) which might cause bilateral disc edema was 
discussed, but found unlikely due to lack of typical symptoms related to increased 
intracranial pressure such as headache, transient visual obscurations, and diplopia. 
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Neuroimaging (MRI) was normal and lumbar puncture was considered redundant. 
The medication regimen of the patient was examined. Since the dosage of 
prednisolone was not changed during the remission of the patient’s symptoms in our 
case, there is no reason to believe that it could be the culprit of his ocular symptoms. 
In addition to steroids, thiazide could possibly provide ocular symptoms indirectly 
through electrolyte disturbances. In this case however, blood electrolytes were 
monitored regularly and showed concentrations within normal range. 
 
 
Possible effects leading to microvasculopathy 
Long-term microangiopathic effects of CyA are well described in the literature, 
especially in studies involving nephrotoxicity. Many articles relate this to an altered 
local endothelin-1 (ET-1) activity, as endothelin-1 increases vascular tone and 
reduces renal glomerular filtration rate (Li et al., 2004). Although endothelin is 
produced in a wide range of cell types, ET-1 is only found in endothelial cells. When 
endothelial damage, hypoxia or ischemia occur, ET-1 is rapidly produced and 
released. ET-1 has also been shown to regulate sodium reabsorption. Finally, effects 
on sympathetic nerve system have been discussed (Elzinga et al., 2000). One study 
demonstrated endothelial dysfunction induced by CyA in an in vitro cell culture 
(Wilasrusmee et al., 2003). The focus is not whether CyA induces vascular 
contraction, but rather how CyA affects the vascular endothelium. Specifically, CyA 
induces ET-1 gene expression and release, with mechanisms that are not completely 
understood. In this study, only ET-1 gene expression proved to induce 
microangiopathy after several mediators were tested. In addition, it was demonstrated 
that CyA stimulated endothelial cells to secrete an excessive amount of ET-1. 
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Another possible interaction with vascular tone in cyclosporine use is its effect on 
nitric oxide (NO) (Li et al., 2004). CyA may interfere with the production of NO, 
leading to increased vessel constriction. NO is produced from l-arginine by 3 
identified isoforms of NO synthase. The synthesis of the different NO synthase 
isoforms, and thereby an altered production of NO, has proved to be interfered by 
chronic CsA use. One study suggested that CyA-induced hypertension is caused by a 
conversion of NO into peroxynitrites (Calo et al., 2000). It is discussed to be caused 
by CyA’s ability to induce production of superoxides (O2-), causing oxidative stress 
where NO molecules are destroyed. The breakdown of peroxynitrites creates NO3-
/NO2- which are even more highly reactive than superoxides. On the other hand, 
other studies are inconclusive and suggest that the effects of reduced acetylcholine 
activity might be the main reason for increased vascular tone rather than a direct 
effect of CyA treatment in transplanted patients (Bracht et al., 1999;Calo et al., 
2000;Calo et al., 2002;Li et al., 2004;Ramzy et al., 2008). 
 
CyA interference with the sympathetic nervous system as a possible cause of 
microvasculopathy has been discussed in several articles, but the results from these 
trials are in many cases inconclusive or conflicting. There are evidence that CyA-
treated heart-transplanted patients with hypertension have an increase in discharge 
from sympathetic nerves. Experimental trials show interference with the sympathetic 
nervous system and increased arterial blood pressure through activation of excitatory 
neural reflexes. In contrast, opposing studies have shown that CyA inhibits 
vasodilatation without affecting sympathetic activity. The variety of results from 
these trials leads to the conclusion that CyA may induce hypertension by impairment 
of peripheral vasodilation or alteration of vascular mechanisms isolated from 
sympathetic nervous regulation.(Scherrer et al., 1990;Lyson et al., 1994;Stein et al., 
1995;Ventura et al., 1997) 
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Some of these potential vascular mechanisms include uncoupling of acetylcholine 
and interference with an endothelial-mediated pathway which regulates the uptake of 
calcium. CyA has also been demonstrated to induce apoptosis by increasing 
expression of pro-apoptotic proteins and decreasing expression of the survival gene 
bcl-2. An upregulated expression of angiotensin II receptors is another possible cause 
of CyA-mediated vasoconstriction that could also be connected with decreased renal 
blood flow due to afferent arteriolar constriction. Increased sensitivity to constrictive 
stimuli has been postulated as well. The cause of is thought to be CyA-induced rise of 
calsium consentrations in smooth muscle cells. Even though many possible effects of 
CyA on vessel tone have been suggested and tested, the cause-effect relationships are 
still to be completely described.(Mason, 1990;Avdonin et al., 1999;Allison, 
2000;Serkova and Christians, 2003) 
 
Future aspects of cyclosporine and other immunosuppressive agents. 
 
Since the first days of CyA development, several immunosuppressive agents have 
become available for clinical use. Tacrolimus has already been mentioned and was 
released in 1997. Another promising alternative for solid organ transplantation are the 
relatively newly released macrolides known as mTOR inhibitors. The need for a new 
immunosuppressive agent with less adverse effects have become clearer after long 
time use of CyA and tacrolimus. The problem is not only the nephrotoxicity and the 
risk of developing cardiovascular disease, but also the fact that chronic rejection still 
remains a major problem. Sirolimus is the most common mTOR inhibitor and has 
shown promising graft survival rates in solid organ transplantation. Another 
interesting feature is the synergy of mTOR inhibitors with CyA, tacrolimus, steroids 
and mycophenolate mofetil. The specific effect of sirolimus on T-cell proliferation 
resembles that of CyA by inhibiting the IL-2 induced proliferation of T-cells. 
However, it is fundamentally different because of its inhibition of the mTOR 
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signalling pathway. Although further studies are required to make conclusions about 
the efficiacy in solid organ graft survival during sirolimus use, trials have shown that 
sirolimus gives reduced rates of nephrotoxicity and hypertension compared with 
CyA. Sirolimus may therefore, either as a monotherapy or in combination with 
traditional immunosuppressive agents, improve adverse effect profiles among 
different patient groups (Neuhaus et al., 2001;Langone and Helderman, 
2004;Everson, 2006;Levy et al., 2006). 
 
Even if sirolimus may reduce many of the complications seen during CyA treatment, 
the mTOR inhibitor itself has troublesome adverse effects. The most important ones 
include metabolic effects, predominantly increased serum blood levels of 
triglycerides and cholesterol. mTOR inhibitors have also shown to decrease uric acid 
concentrations as well as to elevate serum liver enzymes. Finally, myelosuppression 
has been reported, leading to thrombocytopenia, decreased leucocyte count and 
anaemia. Especially in renal failure or impairment, anaemia spells serious problems 
which is complicated by the fact that these patients respond less to supplementary 
erythropoietin (Smith et al., 2003;Taylor et al., 2005). 
 
The future of CyA as an immunosuppressive agent is depending largely on whether 
or not it’s possible to combine CyA with less nephrotoxic agents. It is clear that 
calcineurin inhibitor-sparing regimens will be strictly preferred in order to reduce 
nephrotoxicity and increase graft and patient survival in solid organ transplantation. 
Trials have shown that these non-nephrotoxic regimens allow CyA to be reduced or 
even eliminated in immunosuppressive therapy. Combinations of sirolimus with CyA 
and with tacrolimus have been given most attention, and a thorough analysis of 
efficacy, tolerance and safety of the mTOR inhibitors will show if sirolimus qualify 
as the new standard immunosuppressant. Should this be the case, it is predicted that 
sirolimus will revolutionize the immunosuppression of solid organ transplantation in 
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the same way that CyA did in the 70’s. However, the execution of more randomized 
trials involving large numbers of patients with long-term follow-up is still required 
(Neuhaus et al., 2001;Taylor et al., 2005;Everson, 2006;Guerra et al., 2007).  
 
     References Cited 
 
Adhikary, S. D., S. B. Viswaroop, N. S. Kekre, and G. Gopalakrishnan, 2008, 
Comparative study of graft nephrectomy in pre-cyclosporine and cyclosporine 
era: Urologia Internationalis, v. 80, no. 1, p. 80-83. 
Ahsan, N. et al., 2001, Randomized trial of tacrolimus plus mycophenolate 
mofetil or azathioprine versus cyclosporine oral solution (modified) plus 
mycophenolate mofetil after cadaveric kidney transplantation: results at 2 
years: Transplantation, v. 72, no. 2, p. 245-250. 
Allison, A. C., 2000, Immunosuppressive drugs: the first 50 years and a glance 
forward: Immunopharmacology, v. 47, no. 2-3, p. 63-83. 
Avdonin, P. V., F. Cottet-Maire, G. V. Afanasjeva, S. A. Loktionova, P. Lhote, 
and U. T. Ruegg, 1999, Cyclosporine A up-regulates angiotensin II receptors 
and calcium responses in human vascular smooth muscle cells: Kidney 
International, v. 55, no. 6, p. 2407-2414. 
Avery, R., D. A. Jabs, J. R. Wingard, G. Vogelsang, R. Saral, and G. Santos, 
1991, Optic disc edema after bone marrow transplantation. Possible role of 
cyclosporine toxicity: Ophthalmology, v. 98, no. 8, p. 1294-1301. 
Bolwell, B., R. Sobecks, B. Pohlman, S. Andresen, L. Rybicki, E. Kuczkowski, 
and M. Kalaycio, 2004, A prospective randomized trial comparing cyclosporine 
and short course methotrexate with cyclosporine and mycophenolate mofetil for 
GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation: 
Bone Marrow Transplantation, v. 34, no. 7, p. 621-625. 
Borel, J. F., C. Feurer, H. U. Gubler, and H. Stahelin, 1994, Biological effects of 
cyclosporin A: a new antilymphocytic agent. 1976: Agents Actions, v. 43, no. 3-4, 
p. 179-186. 
Bracht, C., X. W. Yan, H. P. LaRocca, G. Sutsch, and W. Kiowski, 1999, 
Cyclosporine A and control of vascular tone in the human forearm: influence of 
post-transplant hypertension: Journal of Hypertension, v. 17, no. 3, p. 357-363. 
 19
Butterly, D. W., R. F. Spurney, P. Ruiz, R. Griffiths, C. Albrightson, and T. M. 
Coffman, 2000, A role for leukotrienes in cyclosporine nephrotoxicity: Kidney 
International, v. 57, no. 6, p. 2586-2593. 
Calne, R. Y. et al., 1979, Cyclosporin A initially as the only immunosuppressant 
in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers: 
Lancet, v. 2, no. 8151, p. 1033-1036. 
Calne, R. Y., S. Thiru, P. McMaster, G. N. Craddock, D. J. White, D. J. Evans, 
D. C. Dunn, B. D. Pentlow, and K. Rolles, 1998, Cyclosporin A in patients 
receiving renal allografts from cadaver donors. 1978: Journal of the American 
Society of Nephrology, v. 9, no. 9, p. 1751-1756. 
Calo, L., B. Giacon, P. A. Davis, E. Pagnin, A. Piccin, P. Riegler, W. Huber, A. 
Antonello, and A. Semplicini, 2002, Oxidative stress and TGFbeta in kidney-
transplanted patients with cyclosporin-induced hypertension. Effect of 
carvedilol and nifedipine: Clinical Nephrology, v. 58, no. 2, p. 103-110. 
Calo, L., A. Semplicini, P. A. Davis, P. Bonvicini, S. Cantaro, P. Rigotti, A. 
D'Angelo, U. Livi, and A. Antonello, 2000, Cyclosporin-induced endothelial 
dysfunction and hypertension: are nitric oxide system abnormality and 
oxidative stress involved?: Transplant International, v. 13 Suppl 1, p. S413-
S418. 
Cruz, O. A., S. G. Fogg, and G. Roper-Hall, 1996, Pseudotumor cerebri 
associated with cyclosporine use: Am.J.Ophthalmol., v. 122, no. 3, p. 436-437. 
Elzinga, L. W., S. Rosen, E. A. Burdmann, D. C. Hatton, J. Lindsley, and W. M. 
Bennett, 2000, The role of renal sympathetic nerves in experimental chronic 
cyclosporine nephropathy: Transplantation, v. 69, no. 10, p. 2149-2153. 
Everson, G. T., 2006, Everolimus and mTOR inhibitors in liver transplantation: 
opening the "box": Liver Transpl., v. 12, no. 11, p. 1571-1573. 
Gonwa, T. et al., 2003, Randomized trial of tacrolimus + mycophenolate mofetil 
or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric 
kidney transplantation: results at three years: Transplantation, v. 75, no. 12, p. 
2048-2053. 
Grimm, M. et al., 2006, Superior prevention of acute rejection by tacrolimus vs. 
cyclosporine in heart transplant recipients--a large European trial: 
Am.J.Transplant., v. 6, no. 6, p. 1387-1397. 
Guerra, G., T. R. Srinivas, and H. U. Meier-Kriesche, 2007, Calcineurin 
inhibitor-free immunosuppression in kidney transplantation: Transplant 
International, v. 20, no. 10, p. 813-827. 
 20 
Haddad, E. M., V. C. McAlister, E. Renouf, R. Malthaner, M. S. Kjaer, and L. 
L. Gluud, 2006, Cyclosporin versus tacrolimus for liver transplanted patients: 
Cochrane.Database.Syst.Rev., no. 4, p. CD005161. 
Keogh, A., 2004, Calcineurin inhibitors in heart transplantation: Journal of 
Heart and Lung Transplantation, v. 23, no. 5 Suppl, p. S202-S206. 
Langone, A. J., and J. H. Helderman, 2004, Experience with cyclosporine: 
Transplantation Proceedings, v. 36, no. 2 Suppl, p. 59S-63S. 
Levy, G. et al., 2006, Safety, tolerability, and efficacy of everolimus in de novo 
liver transplant recipients: 12- and 36-month results: Liver Transpl., v. 12, no. 
11, p. 1640-1648. 
Li, C., S. W. Lim, B. K. Sun, and C. W. Yang, 2004, Chronic cyclosporine 
nephrotoxicity: new insights and preventive strategies: Yonsei Medical Journal, 
v. 45, no. 6, p. 1004-1016. 
Lyson, T., D. M. McMullan, L. D. Ermel, B. J. Morgan, and R. G. Victor, 1994, 
Mechanism of cyclosporine-induced sympathetic activation and acute 
hypertension in rats: Hypertension, v. 23, no. 5, p. 667-675. 
Margreiter, R., 2002, Efficacy and safety of tacrolimus compared with 
ciclosporin microemulsion in renal transplantation: a randomised multicentre 
study: Lancet, v. 359, no. 9308, p. 741-746. 
Mason, J., 1990, The pathophysiology of Sandimmune (cyclosporine) in man 
and animals: Pediatric Nephrology, v. 4, no. 6, p. 686-704. 
Mayer, A. D., 2002, Chronic rejection and graft half-life: five-year follow-up of 
the European Tacrolimus Multicenter Renal Study: Transplantation 
Proceedings, v. 34, no. 5, p. 1491-1492. 
Mayer, A. D. et al., 1997, Multicenter randomized trial comparing tacrolimus 
(FK506) and cyclosporine in the prevention of renal allograft rejection: a report 
of the European Tacrolimus Multicenter Renal Study Group: Transplantation, 
v. 64, no. 3, p. 436-443. 
McAlister, V. C., E. Haddad, E. Renouf, R. A. Malthaner, M. S. Kjaer, and L. L. 
Gluud, 2006, Cyclosporin versus tacrolimus as primary immunosuppressant 
after liver transplantation: a meta-analysis: Am.J.Transplant., v. 6, no. 7, p. 
1578-1585. 
Nash, R. A. et al., 2000, Phase 3 study comparing methotrexate and tacrolimus 
with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host 
disease after marrow transplantation from unrelated donors: Blood, v. 96, no. 6, 
p. 2062-2068. 
 21
Neuhaus, P., J. Klupp, and J. M. Langrehr, 2001, mTOR inhibitors: an 
overview: Liver Transpl., v. 7, no. 6, p. 473-484. 
O'Grady, J. G., A. Burroughs, P. Hardy, D. Elbourne, and A. Truesdale, 2002, 
Tacrolimus versus microemulsified ciclosporin in liver transplantation: the 
TMC randomised controlled trial: Lancet, v. 360, no. 9340, p. 1119-1125. 
Olyaei, A. J., A. M. de Mattos, and W. M. Bennett, 2001, Nephrotoxicity of 
immunosuppressive drugs: new insight and preventive strategies: 
Curr.Opin.Crit Care, v. 7, no. 6, p. 384-389. 
Paul, L. C., 2001, Overview of side effects of immunosuppressive therapy: 
Transplantation Proceedings, v. 33, no. 3, p. 2089-2091. 
Pichlmayr, R., M. Winkler, P. Neuhaus, P. McMaster, R. Calne, G. Otto, R. 
Williams, C. G. Groth, and H. Bismuth, 1997, Three-year follow-up of the 
European Multicenter Tacrolimus (FK506) Liver Study: Transplantation 
Proceedings, v. 29, no. 5, p. 2499-2502. 
Pirsch, J. D., J. Miller, M. H. Deierhoi, F. Vincenti, and R. S. Filo, 1997, A 
comparison of tacrolimus (FK506) and cyclosporine for immunosuppression 
after cadaveric renal transplantation. FK506 Kidney Transplant Study Group: 
Transplantation, v. 63, no. 7, p. 977-983. 
Prevot, A., D. S. Semama, E. Justrabo, J. P. Guignard, A. Escousse, and J. B. 
Gouyon, 2000, Acute cyclosporine A-induced nephrotoxicity: a rabbit model: 
Pediatric Nephrology, v. 14, no. 5, p. 370-375. 
Ramzy, D., L. C. Tumiati, E. Tepperman, R. Sheshgiri, J. Jackman, M. 
Badiwala, and V. Rao, 2008, Dual immunosuppression enhances vasomotor 
injury: interactive effect between endothelin-1 and nitric oxide bioavailability: 
Journal of Thoracic and Cardiovascular Surgery, v. 135, no. 4, p. 938-944. 
Ratanatharathorn, V. et al., 1998, Phase III study comparing methotrexate and 
tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-
versus-host disease prophylaxis after HLA-identical sibling bone marrow 
transplantation: Blood, v. 92, no. 7, p. 2303-2314. 
Reichart, B. et al., 2001, European multicenter tacrolimus heart pilot study: 
three year follow-up: Journal of Heart and Lung Transplantation, v. 20, no. 2, p. 
249-250. 
Rezzani, R., 2004, Cyclosporine A and adverse effects on organs: histochemical 
studies: Progress in Histochemistry and Cytochemistry, v. 39, no. 2, p. 85-128. 
Scherrer, U., S. F. Vissing, B. J. Morgan, J. A. Rollins, R. S. Tindall, S. Ring, P. 
Hanson, P. K. Mohanty, and R. G. Victor, 1990, Cyclosporine-induced 
 22 
sympathetic activation and hypertension after heart transplantation: New 
England Journal of Medicine, v. 323, no. 11, p. 693-699. 
Serkova, N., and U. Christians, 2003, Transplantation: toxicokinetics and 
mechanisms of toxicity of cyclosporine and macrolides: 
Curr.Opin.Investig.Drugs, v. 4, no. 11, p. 1287-1296. 
Smith, J. M., T. L. Nemeth, and R. A. McDonald, 2003, Current 
immunosuppressive agents: efficacy, side effects, and utilization: Pediatric 
Clinics of North America, v. 50, no. 6, p. 1283-1300. 
Somech, R., and J. Doyle, 2007, Pseudotumor cerebri after allogeneic bone 
marrow transplant associated with cyclosporine a use for graft-versus-host 
disease prophylaxis: Journal of Pediatric Hematology/Oncology, v. 29, no. 1, p. 
66-68. 
Stein, C. M., H. He, T. Pincus, and A. J. Wood, 1995, Cyclosporine impairs 
vasodilation without increased sympathetic activity in humans: Hypertension, v. 
26, no. 4, p. 705-710. 
Stiller, C. R., 1999, Tribute to Jean Francois Borel: a gentleman and a scholar: 
Transplantation Proceedings, v. 31, no. 1-2A, p. 3S-8S. 
Taylor, A. L., C. J. Watson, and J. A. Bradley, 2005, Immunosuppressive agents 
in solid organ transplantation: Mechanisms of action and therapeutic efficacy: 
Crit Rev.Oncol.Hematol., v. 56, no. 1, p. 23-46. 
Taylor, D. O. et al., 1999, A randomized, multicenter comparison of tacrolimus 
and cyclosporine immunosuppressive regimens in cardiac transplantation: 
decreased hyperlipidemia and hypertension with tacrolimus: Journal of Heart 
and Lung Transplantation, v. 18, no. 4, p. 336-345. 
Ventura, H. O., M. R. Mehra, D. D. Stapleton, and F. W. Smart, 1997, 
Cyclosporine-induced hypertension in cardiac transplantation: Medical Clinics 
of North America, v. 81, no. 6, p. 1347-1357. 
Vincenti, F. et al., 2007, Results of an international, randomized trial comparing 
glucose metabolism disorders and outcome with cyclosporine versus tacrolimus: 
Am.J.Transplant., v. 7, no. 6, p. 1506-1514. 
Walter, S. H., H. Bertz, and J. Gerling, 2000, Bilateral optic neuropathy after 
bone marrow transplantation and cyclosporin A therapy: Graefes Archive for 
Clinical and Experimental Ophthalmology, v. 238, no. 6, p. 472-476. 
Wiesner, R. H., 1998, A long-term comparison of tacrolimus (FK506) versus 
cyclosporine in liver transplantation: a report of the United States FK506 Study 
Group: Transplantation, v. 66, no. 4, p. 493-499. 
 23
Wilasrusmee, C., S. M. Da, J. Siddiqui, D. Bruch, S. Kittur, S. Wilasrusmee, and 
D. S. Kittur, 2003, Role of endothelin-1 in microvascular dysfunction caused by 
cyclosporin A: Journal of the American College of Surgeons, v. 196, no. 4, p. 
584-591. 
 
 
